GLP-1 agonists, appetite regulation, metabolic compounds
CAS 910463-68-2
A GLP-1 receptor agonist approved for type 2 diabetes and obesity. Synthetic analog of human glucagon-like peptide-1 with 94% homology.
CAS 2023788-19-2
A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and obesity. First-in-class dual incretin agonist.
CAS 2381089-83-2
A triple G (GLP-1/GIP/Glucagon) receptor agonist in Phase 3 trials for obesity and type 2 diabetes.
A long-acting amylin analog in development for obesity, often combined with semaglutide as CagriSema.
A dual glucagon/GLP-1 receptor agonist in development for obesity and NASH.
A dual glucagon/GLP-1 receptor agonist developed in China for obesity.
CAS 221231-10-3
A fragment of human growth hormone (177-191) claimed to have fat-burning effects without GH side effects.
A peptidomimetic designed to induce apoptosis in adipose tissue blood vessels.